Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $530.11, for a total transaction of $5,036,045.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $171,990,478.73. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Stock Down 2.7%

UTHR traded down $14.16 during trading on Tuesday, hitting $515.50. 343,386 shares of the company’s stock were exchanged, compared to its average volume of 494,773. United Therapeutics Corporation has a fifty-two week low of $292.34 and a fifty-two week high of $609.35. The stock has a market cap of $22.11 billion, a P/E ratio of 18.44, a PEG ratio of 1.82 and a beta of 0.59. The business’s 50 day moving average is $539.13 and its two-hundred day moving average is $535.14.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the firm posted $6.41 earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.32 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of United Therapeutics during the 2nd quarter worth $2,868,735,000. Avoro Capital Advisors LLC raised its position in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC grew its position in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.